Karyopharm Therapeutics, Inc. (KPTI)

Oncology Corporate Profile

Stock Performance

10.8300
0.2000

3 Month Stock History Chart

HQ Location

2 Mercer Road
Natick, MA 1760

Company Description

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Karyopharm's SINE compounds function by blocking the XPO1, preventing the export of various proteins out of the nucleus. SINE compounds have shown biological activity in models of cancer, autoimmune disease, certain viruses, and wound-healing.

Website: http://www.karyopharm.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
selinexor / KPT-330XPO1 inhibitorAcute Myelogenous Leukemia (AML)III
selinexor / KPT-330XPO1 inhibitorAcute Myelogenous Leukemia (AML)II
selinexor / KPT-330XPO1 inhibitorDiffuse large B-cell Lymphoma (DLBCL)II
KPT-330XPO1 inhibitorGlioblastoma Multiforme (GBM)II
selinexor / KPT-330XPO1 inhibitorCutaneous T-cell Lymphoma (CTCL)I
selinexor / KPT-330XPO1 inhibitorMultiple MyelomaI
selinexor / KPT-330XPO1 inhibitorPediatric cancerI
selinexor / KPT-330XPO1 inhibitorProstate cancerI
selinexor / KPT-330XPO1 inhibitorSarcomaI
selinexor / KPT-330XPO1 inhibitorVarious cancer typesI

View additional information on product candidates here »

Source: http://www.karyopharm.com

Recent News Headlines

8/21/2017 06:20 am

8/21/2017 06:20 am

8/21/2017 06:20 am

8/9/2017 06:18 pm

8/9/2017 06:18 pm

8/9/2017 06:18 pm

8/8/2017 06:18 am

8/8/2017 06:18 am

8/8/2017 12:18 am

8/1/2017 06:18 pm

8/1/2017 12:22 am

7/26/2017 12:18 am

7/23/2017 12:18 pm

7/14/2017 12:18 pm

7/14/2017 12:18 pm

7/3/2017 06:18 am

7/3/2017 06:18 am

7/3/2017 06:18 am

7/3/2017 06:18 am

7/3/2017 06:18 am

6/26/2017 12:19 pm

6/26/2017 12:19 pm

6/23/2017 06:18 am

6/23/2017 12:18 am

6/7/2017 12:18 pm